Monte Rosa Therapeutics, Inc. (GLUE)
13.84
-0.54
(-3.76%)
USD |
NASDAQ |
Sep 04, 16:00
13.97
+0.13
(+0.94%)
After-Hours: 20:00
Monte Rosa Therapeutics Research and Development Expense (Quarterly) : 46.05M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 46.05M |
| March 31, 2026 | 42.04M |
| December 31, 2025 | 39.89M |
| September 30, 2025 | 34.58M |
| June 30, 2025 | 28.53M |
| March 31, 2025 | 30.14M |
| December 31, 2024 | 36.80M |
| September 30, 2024 | 25.51M |
| June 30, 2024 | 26.00M |
| March 31, 2024 | 25.13M |
| December 31, 2023 | 25.29M |
| September 30, 2023 | 26.47M |
| June 30, 2023 | 27.68M |
| Date | Value |
|---|---|
| March 31, 2023 | 25.60M |
| December 31, 2022 | 22.19M |
| September 30, 2022 | 18.77M |
| June 30, 2022 | 18.77M |
| March 31, 2022 | 16.78M |
| December 31, 2021 | 17.32M |
| September 30, 2021 | 14.53M |
| June 30, 2021 | 14.17M |
| March 31, 2021 | 8.999M |
| December 31, 2020 | 9.64M |
| September 30, 2020 | 5.301M |
| June 30, 2020 | 4.783M |
| March 31, 2020 | 3.744M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Nurix Therapeutics, Inc. | 85.40M |
| Gilead Sciences, Inc. | 1.69B |
| Ironwood Pharmaceuticals, Inc. | 21.96M |
| Capricor Therapeutics, Inc. | 28.57M |
| Cue Biopharma, Inc. | 48.98M |